These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35000806)
41. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F; Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945 [TBL] [Abstract][Full Text] [Related]
42. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172 [TBL] [Abstract][Full Text] [Related]
43. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406 [TBL] [Abstract][Full Text] [Related]
44. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure. Young MJ; Kanki M; Karthigan N; Konstandopoulos P Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730 [TBL] [Abstract][Full Text] [Related]
45. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B; Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868 [TBL] [Abstract][Full Text] [Related]
46. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Dhillon S Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669 [TBL] [Abstract][Full Text] [Related]
47. Eplerenone in chronic heart failure with depressed systolic function. Volterrani M; Iellamo F Int J Cardiol; 2015 Dec; 200():12-4. PubMed ID: 26044084 [TBL] [Abstract][Full Text] [Related]
49. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641 [TBL] [Abstract][Full Text] [Related]
50. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B; JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441 [TBL] [Abstract][Full Text] [Related]
51. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223 [TBL] [Abstract][Full Text] [Related]
52. Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. Bayoumi E; Lam PH; Dooley DJ; Singh S; Faselis C; Morgan CJ; Patel S; Sheriff HM; Mohammed SF; Palant CE; Pitt B; Fonarow GC; Ahmed A Am J Med; 2019 Jan; 132(1):71-80.e1. PubMed ID: 30240686 [TBL] [Abstract][Full Text] [Related]
53. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706 [TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322 [TBL] [Abstract][Full Text] [Related]
55. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P; Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500 [TBL] [Abstract][Full Text] [Related]
56. Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. Frankenstein L; Katus HA; Grundtvig M; Hole T; de Blois J; Schellberg D; Atar D; Zugck C; Agewall S; Eur J Clin Pharmacol; 2013 Oct; 69(10):1747-55. PubMed ID: 23743778 [TBL] [Abstract][Full Text] [Related]
57. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Rossello X; Ferreira JP; Pocock SJ; McMurray JJV; Solomon SD; Lam CSP; Girerd N; Pitt B; Rossignol P; Zannad F Eur J Heart Fail; 2020 May; 22(5):834-844. PubMed ID: 32077220 [TBL] [Abstract][Full Text] [Related]
58. Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Monzo L; Ferreira JP; Abreu P; Szumski A; Böhm M; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Girerd N; Vincent J; Zannad F; Rossignol P J Hypertens; 2020 Mar; 38(3):420-425. PubMed ID: 31584516 [TBL] [Abstract][Full Text] [Related]
59. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Deedwania PC; Ahmed MI; Feller MA; Aban IB; Love TE; Pitt B; Ahmed A Eur J Heart Fail; 2011 May; 13(5):551-9. PubMed ID: 21393298 [TBL] [Abstract][Full Text] [Related]
60. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Rossignol P; Girerd N; Bakris G; Vardeny O; Claggett B; McMurray JJV; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Spanyers S; Vincent J; Fay R; Lamiral Z; Solomon SD; Zannad F; Pitt B Eur J Heart Fail; 2017 Jun; 19(6):792-799. PubMed ID: 27868385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]